Blog
Merck’s Keytruda fails a study for early stomach cancer following metastatic disease victory
Source – Merck Inhibiting immune checkpoints hasn’t been very effective against stomach cancer. Merck has now added another failure to ...
Following Merck’s example, Bristol Myers Squibb has filed a lawsuit criticizing the IRA’s Medicare negotiations
Source – Bristol Myers Squibb Following Merck’s shocking lawsuit that contested several provisions of the Inflation Reduction Act (IRA), Bristol-Myers ...
In a migraine head-to-head matchup, Pfizer’s Nurtec defeats Eli Lilly’s Emgality
Source – PR Newswire In a side-by-side comparison, Emgality did not outperform Pfizer’s Nurtec in preventing episodic migraines, Lilly said ...
Novo Nordisk plans to stop compounded versions of Ozempic and Wegovy with fresh litigation
Source – Fierce Pharma Novo allegedly filed separate lawsuits against health spas, clinics, and pharmacies in Florida, New York, Tennessee, ...
DICE Therapeutics will be acquired by Lilly in order to advance immunology innovation
Source – Eli Lilly On June 20, 2023 a formal deal for Lilly to purchase DICE was announced by Eli ...
Lilly Launches “Tap the Cap” with Adam Duvall, the American Diabetes Association, and other partners
Source – Eli Lilly 20 June 2023, together with the American Diabetes Association (ADA) and professional baseball player Adam Duvall, ...
At the 83rd Scientific Sessions of the American Diabetes Association, Lilly will discuss fresh findings in the management of diabetes and obesity
Source – Eli Lilly On 20 June 2023 at the American Diabetes Association’s (ADA) 83rd Scientific Sessions in San Diego ...
Talazoparib Plus Enzalutamide for HRR Gene-Altered mCRPC Receives FDA Approval
Source – FDA On June 20, 2023, the combination of talazoparib (Talzenna) and enzalutamide (Xtandi) has been approved by the ...
Takeda Unveils Complete Phase III Trial Results for HYQVIA as Maintenance Therapy in CIDP at PNS Annual Meeting
Source: Takeda Takeda on June 20, 2023, released the complete findings from the pivotal Phase III ADVANCE-CIDP 1 clinical trial, ...
Argenx receives FDA approval for the first gMG subcutaneous treatment
Source – Argenx Argenx has claimed an FDA clearance that might increase its market share in the increasingly competitive market ...
Pfizer Joins Prostate Cancer PARP Showdown: A Three-Way Battle for Breakthrough Treatment
Pfizer expects that the FDA’s approval of Talzenna, a PARP inhibitor, for castration-resistant prostate cancer (CRPC) would enable it to ...
PhRMA moves forward with the Medicare pricing talks
The National Infusion Centre Association, the Global Colon Cancer Association, and Pharmaceutical Research and Manufacturers of America (PhRMA) have all ...
CDC advisory group reviews GSK and Pfizer RSV vaccinations
Source – Fierce Pharma On June 21, 2023, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease ...
Vyvanse Joins Adderall in Short Supply as Takeda’s Rival Faces Shortages
Source – Fierce Pharma A competitor medication from Takeda is currently in low supply after a lengthy scarcity of the ...
The US FDA has approved the use of Jardiance (empagliflozin) to treat type II diabetes in children and adolescents aged 10 and older
Source – Eli Lilly On June 21, 2023, Boehringer Ingelheim and Eli Lilly and Company announced that the US Food ...
BioSenic’s stock declines as it discontinues bone-repair treatment
Source – BioSenic A Phase II b study of ALLOB, a stem cell-derived treatment intended to quicken bone fracture repair, ...
Weight-Loss Medications Market Projected to Reach $60 Billion in 10 Years
According to a Morningstar analyst, frantic demand for pharmaceuticals to treat obesity from Novo Nordisk, Eli Lilly, and other companies ...
Boehringer Ingelheim’s Zantac arbitration is won by Sanofi
Source – Sanofi On 20 June 2023 in Paris, Sanofi reports that the International Chamber of Commerce tribunal has rejected ...
Rani’s ‘robotic’ tablet administers an injection of an osteoporosis medication
Source – Rani Therapeutics In a first-in-human research, US biotech Rani Therapeutics demonstrated that its oral version of an osteoporosis ...
High Cost of New Cancer Drugs and Lack of Awareness Impede Adoption in the US
A new survey conducted by healthcare research firm Sermo revealed that oncologists in the United States perceive pricing as the ...
A monovalent COVID booster is advised by the FDA advisory group
The FDA advisory panel recently reached a unanimous conclusion regarding COVID-19 vaccinations for the upcoming autumn. They recommended a transition ...
Vera Therapeutics Atacicept Shows Efficacy and Safety in IgAN at ERA Congress
Soure: Vera Therapeutics On June 17, 2023, Vera Therapeutics, a biotechnology company focused on immunological diseases, announced positive results from ...
Comprehensive Guide to mRNA Vaccines: Advancements in COVID-19 Immunization
Introduction At our organization, we are dedicated to providing valuable information on the latest advancements in COVID-19 vaccines. In this ...
FDA Accepts sNDA for NALIRIFOX as First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma
Source: Ipsen Pharma The FDA has accepted a supplemental new drug application (sNDA) for the combination of liposomal irinotecan, 5-fluorouracil, ...
Significant Surge in Biologic Medications for Lupus Treatment as Rheumatologists Shift Away from Traditional Off-Label Therapies
A recent analysis conducted by Spherix Global Insights reveals a notable increase in the utilization of new biologic drugs, namely ...
Roche’s Columvi and AbbVie’s Epkinly: The Battle for Breakthroughs in Large b Cell Lymphoma Treatment
Roche’s Columvi (glofitamab) receives FDA accelerated approval for treatment of Large b Cell Lymphoma, sparking a rivalry with AbbVie and ...
Merck Completes Acquisition of Prometheus Biosciences, Expanding Pipeline with Potential Breakthrough Treatment
Source: Merck On June 16, 2023, Merck announced the successful completion of its acquisition of Prometheus Biosciences, making Prometheus a ...
Keytruda Triumphs: Promising Progression-Free Survival in HER2-Positive Gastric Cancer
Source: Merck Merck’s renowned cancer drug, Keytruda, may soon see an updated label for its effectiveness in treating HER2-positive stomach ...
Adcetris Breakthrough: Six-Year Survival Data Reinforce Its Impact in Hodgkin Lymphoma Treatment
Seagen has made a significant announcement regarding the updated U.S. Prescribing Information (PI) for Adcetris (brentuximab vedotin). The update includes ...
Groundbreaking Clinical Trial Confirms Effectiveness of Emgality in Preventing Episodic Migraines
Source: Eli Lilly and Company On June 16, 2023, Eli Lilly and Company released the findings of the CHALLENGE-MIG clinical ...
